Results 41 to 49 of about 8,326 (49)

High dose simvastatin and adverse muscle effects

Universa Medicina, 2016
High blood cholesterol, or hyperlipidemia, is a cardiovascular risk factor. Surveys have demonstrated that 35.6% of adults in the United States suffer from hyperlipidemia.(1) Currently there are various therapeutic regimens available for hyperlipidemia ...
Yenny Yenny
doaj   +1 more source

Propolis supplementation can reduce serum level of interleukin-6, C-reactive protein, and tumor necrosis factor-α: an updated systematic review and dose-response meta-analysis on randomized clinical trials

Journal of Health, Population and Nutrition
Background New evidence suggested that propolis might reduce serum levels of inflammatory mediators; therefore, in this study we aimed to prove the potential effect of propolis on serum levels of interleukin-6 (IL-6), C-reactive protein (CRP), and tumor ...
Ali Gholami, Negar Dinarvand, Mitra Hariri   +2 more
doaj   +1 more source

Comparison of atherogenic indices for predicting the risk of metabolic syndrome in Southwest Iran: results from the Hoveyzeh Cohort Study (HCS)

Diabetology & Metabolic Syndrome
Background Metabolic syndrome (MetS) is a cluster of risk factors related to diabetes and cardiovascular disease (CVD). Given that early identification of MetS might decrease CVD risk, it is imperative to establish a simple and cost-effective method to ...
Hossein Babaahmadi‐Rezaei, Maedeh Raeisizadeh, Vahid Zarezade, Kourosh Noemani, Ahmad Mashkournia, Hossein Ghaderi-Zefrehi   +5 more
doaj   +1 more source

Association of urinary bisphenol A with hyperlipidemia and all-cause mortality: NHANES 2003-2016.

PLoS ONE
BackgroundThe connection between urinary bisphenol A (BPA) and hyperlipidemia is still unclear, and few studies have evaluated whether urinary BPA affects mortality among individuals with hyperlipidemia.
Lijuan Guo, Pin Zhao, Shilong Xue, Zhaowei Zhu   +3 more
doaj   +1 more source

Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study

Therapeutic Advances in Endocrinology and Metabolism
Background: The causes of cardiovascular disease are complex, with hyperlipidemia being a major factor in its development. The connection between peptic ulcer disease (PUD) and hyperlipidemia is unclear, and there have been no thorough studies on the ...
Hui-Hsia Hsieh, Wan-Yi Lee, Cheng-Li Lin, Chi-Hua Chen, Fuu-Jen Tsai, Bang-Jau You, Ni Tien, Yi-Jen Fang, Yun-Ping Lim   +8 more
doaj   +1 more source

Systemic lupus erythematosus presenting with slurred speech: a case report

Journal of Medical Case Reports
Background Systemic lupus erythematosus is a chronic autoimmune disease with heterogeneous clinical manifestations. Neuropsychiatric involvement is relatively common in systemic lupus erythematosus; however, isolated dysarthria or slurred speech is an ...
Reza Azizi Malamiri, Negar Dinarvand, Mohammad Reza Fathi   +2 more
doaj   +1 more source

Pediatric hyperlipidemia

Indian Heart Journal
The leading cause of mortality worldwide is atherosclerotic cardiovascular disease. Atherosclerotic plaques are well known to originate early in the childhood.
Ankit Garg, S. Radhakrishnan
doaj   +1 more source

Association between cooking patterns and the prevalence of hyperlipidemia in Eastern China

BMC Public Health
Background Hyperlipidemia is a major risk factor for many diseases. Previous studies have shown that diet is closely associated with hyperlipidemia. However, the relationship between cooking methods and hyperlipidemia remains unclear.
Bin Cui, Wen Kai Yuan, Linda Dong-Ling Wang, Fu Rong Wang, Jing Peng, Jian Ying Ma, Xiang Chen, Mei Yin Xu, Jun Ke, Yi Tian   +9 more
doaj   +1 more source

α-Ketoglutarate prevents hyperlipidemia-induced fatty liver mitochondrial dysfunction and oxidative stress by activating the AMPK-pgc-1α/Nrf2 pathway

Redox Biology
α-Ketoglutarate (AKG), a crucial intermediate in the tricarboxylic acid cycle, has been demonstrated to mitigate hyperlipidemia-induced dyslipidemia and endothelial damage.
Danyu Cheng, Mo Zhang, Yezi Zheng, Min Wang, Yilin Gao, Xudong Wang, Xuyun Liu, Weiqiang Lv, Xin Zeng, Konstantin N. Belosludtsev, Jiacan Su, Lin Zhao, Jiankang Liu   +12 more
doaj   +1 more source